Neuro-Oncology
NF2-related schwannomatosis
Dec. 13, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Intramedullary spinal cord metastatic tumors
- Updated 12.21.2022
- Released 05.09.1997
- Expires For CME 12.21.2025
Intramedullary spinal cord metastatic tumors
Introduction
Overview
Intramedullary spinal cord metastasis refers to invasion of the spinal cord by solid tumors that arise elsewhere in the body. It is a relatively rare cause of myelopathy in patients with cancer; compression of the spinal cord by epidural metastatic tumor occurs far more often. Local back pain or radicular or referred pain in a limb is the most common initial symptom. Patients can go on to develop a transverse myelopathy, a Brown-Sequard syndrome, or an ascending or descending myelopathy. The course of the illness is subacutely progressive. The most common primary tumors arise in the lung and breast. MRI is the diagnostic procedure of choice. The prognosis is poor: the majority of patients survive fewer than four months. The cause of death is usually widespread metastatic disease. Radiation therapy is the treatment of choice. Most patients achieve stabilization of spinal cord function, and some patients improve.
Key points
• Intramedullary spinal cord metastasis is an uncommon cause of myelopathy in patients with systemic cancer. | |
• It presents as a painful, subacutely progressive myelopathy. | |
• Untreated, it causes irreversible paraplegia or tetraplegia. | |
• Treatment with radiotherapy, if performed when the patient can still walk, may stabilize, if not improve, spinal cord function. |
Historical note and terminology
The term intramedullary spinal cord metastasis refers to invasion of the parenchyma of the spinal cord by solid tumors that arise elsewhere in the body. Willis was the first to review the pathologic aspects of the subject (49). He pointed out that they are usually multiple, that syringomyelia and hematomyelia can be complications, that carcinoma of the lung and breast are the most frequent primary tumors, and that cerebral metastases are also often present. He hypothesized that intramedullary spinal cord metastases spread to the cord hematogenously or by direct extension from leptomeningeal deposits. Finally, he found that the frequency of intramedullary spinal cord metastases is hard to determine, because the spinal cord is seldom examined at autopsy. The condition is so uncommon that no major clinical series appeared until 1972, and it contained only 9 patients (06). The authors found that the neurologic features are identical to those of compression of the spinal cord by epidural metastatic tumor, that the myelogram is often normal, and that radiation therapy is the treatment of choice. Schiff and O'Neill reported the largest clinical series (40 patients) (41). They concluded that long-term survival is poor because of widespread metastatic disease and that radiation treatment preserves but does not restore neurologic function.
Clinical manifestations
Presentation and course
• Intramedullary spinal cord metastatic tumor can present as transverse myelopathy, Brown-Sequard syndrome, ascending or descending myelopathy, or as a late feature of leptomeningeal carcinomatosis. | |
• The course is subacutely progressive. | |
• The most common primary tumors are lung and breast cancer and melanoma. | |
• Most patients are known to have cancer when spinal cord symptoms begin. |
Neurologic features. Local back pain and radicular or referred pain in a limb are the most common initial symptoms (05; 50). Aggravation of pain with cough, straining at stool, deep inspiration and straight leg raising, and vertebral percussion tenderness are often present. These features, so typical of extradural compression of a nerve root, probably come about as a result of the frequent location of intramedullary metastatic tumor in the dorsal horn of the spinal cord (13; 04). Weakness of one arm or leg, another common early symptom, develops with tumor in the medial portion of the lateral column or in the ventral horn.
Later in the course of the illness, a variety of spinal syndromes may appear:
(1) The most common is transverse myelopathy, with spastic paraparesis or tetraparesis, a sensory level to pinprick and temperature that accurately corresponds to the anatomic site of the tumor, and urinary incontinence or retention (11; 05). | |
(2) A Brown-Sequard syndrome of limb paralysis and contralateral spinothalamic sensory loss, or at least markedly asymmetric weakness, is found in 19% of patients (44). This reflects the unilateral location of the tumor in the spinal cord (13; 04). | |
(3) Some patients present with an ascending myelopathy (a rising sensory level and paraplegia that becomes tetraplegia) or a descending myelopathy (spastic, hyperreflexic paraplegia that evolves to flaccid paraplegia with areflexia). The pathologic basis of these patterns of progression is either necrosis of the spinal cord, which is a vascular complication of the tumor, or the accumulation of more and more metastases in the cord (02; 03; 18; 11; 05; 08; 50). The secondary necrosis of the spinal cord may result in segmental differences between the clinical deficit and the actual level of the tumor. | |
(4) Patients with neurologic signs of leptomeningeal metastases, such as spinal root and cranial nerve signs, may develop long-tract signs as meningeal deposits invade the spinal cord by direct extension (04; 11; 05). |
Several classic neurologic features of intramedullary glioma have not been reported in spinal cord metastasis, including muscle atrophy and fasciculations, syringomyelic dissociation of sensory loss, sacral sparing, and early, rather than late, involvement of bladder and bowel function.
The course of the myelopathy is subacutely progressive in most patients. The median duration of symptoms before diagnosis is 3 weeks, with a range of one day to six years (44). The neurologic deficit develops in less than a week in 17% of patients, less than a month in 58%, and less than six months in 97% (05). The rate of progression of the deficit is often uneven. There may be sudden changes in signs and symptoms. Symptoms may be stable for weeks and then worsen quickly. A patient who has had only pain for weeks may develop paraplegia over a few days' time (03; 18; 15; 05; 08; 45). The reason for this is that intramedullary spinal cord metastases are well demarcated. As they grow, they displace but do not infiltrate the surrounding neural tissue. Clinical symptoms may be minor. When the tumor reaches a certain size, it interferes with the vascular supply of the spinal cord and causes infarction of the segments that contain tumor and are adjacent to tumor. When this occurs, the signs and symptoms progress rapidly (03). Rarely, the disease pursues a chronic, slowly progressive course (50; 22).
Oncologic features. In a literature review of 138 cases of intramedullary spinal cord metastasis, the most common primary tumors were lung and breast cancer and melanoma (44), similar to what is noted with brain metastases. The median age of the patients was 56 years, with a range of four to 82 years. Children have seldom been reported (06). More men are affected than women because lung cancer, the most common primary tumor, is more prevalent in men (44; 43).
Most patients are known to have cancer when spinal cord symptoms begin. The median interval between the diagnosis of cancer and the appearance of symptoms of intramedullary spinal cord metastatic tumor is 16 months, but the interval may be several years (44). Intramedullary spinal cord metastasis usually occurs in the setting of widespread metastatic disease outside the nervous system. Tumor is present in lung, bone, and other sites in 55% of patients (44). The spinal cord is occasionally the first site of metastatic disease, particularly in long-term survivors of lung cancer (11; 05; 09; 10). The reason is that the blood-central nervous system barrier is relatively impermeable to chemotherapeutic agents; therefore, the spinal cord becomes a sanctuary for growing tumor cells. In 19% to 26% of patients diagnosed with intramedullary spinal cord metastasis, it is the presenting feature of an occult malignancy (44; 26). This high figure is surprising and probably reflects publication bias. Myelopathy of unknown cause is a dramatic presentation that may prompt complete diagnostic evaluation or transfer to a tertiary care facility and subsequent report. In contrast, patients with widespread metastatic disease who develop paraplegia as a terminal event may not be worked up but given only palliative care (11).
In many patients, the spinal cord is not the only site of metastasis in the central nervous system. Brain metastasis is present in 61% of patients (44). Leptomeningeal metastatic disease has been found in 17% of patients, mainly in those with small cell carcinoma of the lung (19). It is not clear whether the intramedullary spinal cord metastasis resulted from independent, blood-borne spread or from the direct extension of meningeal tumor (48; 33; 41).
Prognosis and complications
The median survival of patients with intramedullary spinal cord metastasis is four months (range, 4 days to 5 years) (44). Two studies concluded that patients with breast cancer survive longer than those with lung cancer, but the studies were retrospective and had few patients; therefore, the conclusion is probably not reliable (41; 24). Untreated, metastatic tumor destroys the spinal cord; hence, the prognosis for preservation or recovery of spinal cord function in untreated patients is poor. The cause of death is usually widespread systemic and cerebral metastatic disease (05).
Specific complications of intramedullary spinal cord metastases are not mentioned in the literature. Patients who survive long are susceptible to all the complications of chronic spinal cord injury.
Clinical vignette
A 49-year-old smoker noticed clubbing of his fingers late in 1989. His work up disclosed non-small-cell carcinoma of the lung, metastatic to the adrenal glands and the brain.
His brain metastases were asymptomatic. He was treated with cranial irradiation and, between December 1989 and April 1990, received four cycles of systemic chemotherapy. He was without neurologic symptoms until mid-April 1990, when he noticed low back pain and numbness and tingling in both great toes. Over the next 3 weeks, the paresthesias spread throughout the lower limbs. He also noticed weakness in both lower limbs and an unsteady gait. Micturition, defecation, sexual function, and his upper limbs were normal. When examined on May 11, 1990, his mental status and cranial nerves were normal. There was mild weakness of the left iliopsoas, quadriceps, tibialis anterior, and right quadriceps muscles. There was no spasticity or muscle atrophy. The deep tendon reflexes were absent at the knees, 3+ at the ankles, and 2+ in the upper limbs. The plantars were flexor. Light touch and pinprick were decreased bilaterally in L3, L4, and L5 dermatomes. Dermatomes above and below were spared. MRI was consistent with an intramedullary metastatic tumor.
Dexamethasone and spinal cord radiation therapy were started. By June 1, he could no longer walk because of worsening leg weakness. Numbness had risen to his buttocks, but the penis and scrotum were spared. On June 4, a bladder catheter was required because of urinary retention. The tumor was surgically excised on June 18, 1990. He died of progressive metastatic disease on September 21, 1990. His surgery did not improve but did stabilize his spinal cord function.
Biological basis
Etiology
The spread of malignant cells from solid tumors outside the spinal cord is the cause of intramedullary spinal cord metastasis.
Pathology and pathogenesis
• Most intramedullary spinal cord metastatic tumors result from hematogenous spread of tumor cells. | |
• Direct extension from leptomeningeal deposits of tumor is a less common route. | |
• Perineural spread to the cord from a peripheral site is the least common. | |
• Necrosis of the spinal cord above or below the tumor may lead to syringomyelia or hematomyelia. |
Two pathologically distinct forms of intramedullary metastatic tumor occur and indicate spread to the spinal cord by 2 different routes. In most patients, a mass lies deep within the cord, the result of hematogenous spread of tumor.
Less often, focal or multifocal direct extension of leptomeningeal metastatic tumor across the pia mater into the parenchyma of the cord occurs (49; 04).
Intramedullary spinal cord metastasis (leptomeningeal source) (photomicrograph)
(Left) A cross section of the spinal cord shows dense infiltration of the leptomeninges by metastatic carcinoma. (Hematoxylin-eosin; x8) (Right) Detail from the previous section showing direct invasion of tumor across the pia mate...
Jayakumar and colleagues described a third mechanism of spreadperineural invasion (17). They reported a patient with breast cancer that had metastasized to the left brachial plexus. She developed paraparesis, and MRI showed an intramedullary metastasis at C6-C7. There was no pathological verification, but the authors' idea, that tumor reached the spinal cord by perineural spread, as in head and neck cancer, is reasonable.
In large series, blood-borne metastases were evenly distributed along the length of the spinal cord (44). Intramedullary metastases are multiple in at least 15% to 23% of patients. This is likely an underestimate because the cervical cord is seldom examined at autopsy and because many metastases are microscopic in size and easily missed at autopsy (04; 05; 33). The spinal cord may be grossly distorted. It may be evenly or unevenly enlarged and fusiform or irregular in outline (04; 11; 05). If the tumor is small, the uncut cord appears grossly normal (13; 04). The dorsal root may be enlarged as the result of centrifugal spread of tumor from the cord into it (04). On cut section, the tumor is round, well demarcated from the surrounding spinal cord tissue, and may occupy many adjacent segments (13; 04; 05).
Most often, the tumor lies in the ventral part of the dorsal horn or the medial portion of the lateral column, with sparing of the lateral portion (13; 04).
Clinical correlates of that include the frequent early occurrence of ipsilateral segmental pain, paresthesias, and monoparesis (05; 50). The center of the tumor is usually necrotic.
Necrosis of the spinal cord may occur as a complication of the tumor (13; 04). It plays a part in the progression of the myelopathy and is responsible for sudden changes in neurologic signs, sudden acceleration in the pace of deterioration, and a discrepancy between the segmental level of the clinical deficit and that of the tumor. A cone-shaped or pencil-shaped zone of necrosis may extend above and below the tumor (13; 04; 50).
Intramedullary metastatic tumor with pencil-shaped necrosis of the spinal cord (photomicrograph)
(Left) Two symmetrically placed, intramedullary metastatic tumors have destroyed the first sacral segment of the spinal cord. (Hematoxylin-eosin; x7.8) (Center) Rostral to the tumors, the entire fifth lumbar segment has undergone ...
This unusual infarct is probably due to compression of the central artery of the spinal cord by the intramedullary tumor (15; 13). The rising front of necrosis may lead to a rising sensory level on the trunk and may turn paraplegia into tetraplegia (50). Descending necrosis may cause spastic, hyperreflexic paraplegia to become flaccid and areflexic (50). Cavitation of the zone of necrosis may give rise to a secondary syringomyelia, as in intramedullary gliomas (08). Hemorrhage above and below the tumor, similar to pencil-shaped necrosis in location and probably cause, and bleeding into the tumor itself can also occur as complications (20; 13).
Epidemiology
• Spinal cord compression by epidural tumor is 15 to 20 times more common than intramedullary spinal cord metastatic tumor as a cause of clinical myelopathy. | |
• Lung and breast cancers and melanoma are the most common primary tumors among intramedullary spinal cord metastases. |
In large autopsy studies, the frequency of intramedullary spinal cord metastasis ranges widely, from 0.9% to 2.1% of patients with cancer (04; 33). There are 2 reasons for the discrepancy. The first is selection bias. Some series were prospective, with every spinal cord examined, but others were retrospective, with exclusion of many cancer patients because their cords had not been removed at autopsy (49; 04). An even greater problem common to all autopsy studies is the sampling procedure. Many metastases are microscopic, and an indeterminate number of them will be overlooked when only a few blocks of spinal cord are examined microscopically (04).
Autopsy series by their very nature present a picture of end stage disease and the presence of micrometastatic disease at time of death may not hold substantial clinical relevance. A comparison with metastatic epidural spinal cord compression gives a clearer, more workable, and more accurate idea of the frequency of intramedullary spinal cord metastasis as a cause of clinical myelopathy among cancer patients. In four retrospective studies of spinal cord metastases, 94% to 97% of patients had epidural spinal cord compression, and 3% to 6% of patients had intramedullary metastasis (See Table 1).
Table 1. Relative Frequency of Intramedullary Spinal Cord Metastatic Tumor and Metastatic Epidural Spinal Cord Compression
(41) | |
• Study years: 1980 to 1993 | |
(45) | |
• Study years:1975 to 1987 | |
(06) | |
• Study years: 1968 to 1970 | |
(Winkelman, unpublished data) | |
• Study years: 1984 to 1986 | |
Approximately 300 cases of intramedullary spinal cord metastasis have been reported (44). The primary tumor in half of these patients was lung carcinoma. The next most common were breast cancer (16%), melanoma (6%), renal-cell carcinoma (5%), colorectal cancer (5%), and lymphoma (5%). Costigan and Winkelman provided data on the frequency with which specific tumors spread to the cord: melanoma (5.6%), lung (2.8%), and breast cancer (1.3%). Small cell was the most frequent histologic type of lung cancer to spread to the spinal cord (04).
Differential diagnosis
Confusing conditions
In patients known to have cancer. The diagnosis of intramedullary spinal cord metastasis in a patient known to have cancer is a different clinical problem than in a patient not known to have a malignancy. A myelopathy that arises during the course of a systemic malignancy is most often due to compression by an epidural metastatic tumor. There are few oncologic or neurologic differences between intramedullary metastasis and epidural compression. Certain tumors (eg, adenocarcinoma of the prostate, sarcomas, and myeloma) commonly spread to the spinal column and then extend to the spinal epidural space but rarely metastasize to the intramedullary spinal cord (02). The neurologic deficit of intramedullary metastasis often evolves over weeks, whereas that of epidural cord compression more often progresses over days (05). Intramedullary spinal cord metastasis frequently presents as a Brown-Sequard syndrome, whereas metastatic epidural spinal cord compression rarely does (41). However, metastatic epidural spinal cord compression is so much more common than intramedullary metastasis that it must always be considered the more likely diagnosis until excluded by MRI or myelography. Once metastatic epidural spinal cord compression has been eliminated from the differential diagnosis, the physician is faced with a clinical problem that can be formulated as a noncompressive myelopathy in a patient with cancer. Intramedullary spinal cord metastasis, delayed radiation myelopathy, paraneoplastic myelopathy, immune checkpoint inhibitor-associated myelitis, and leptomeningeal metastasis are the major causes.
Intramedullary metastasis versus radiation myelopathy. The neurologic features by which these differ are the presence of pain, the mode of onset, and the tempo of progression. Pain, as an early or prominent symptom, favors the diagnosis of intramedullary metastasis. Local back or neck pain, deep aching pain referred to a limb, or frank radicular pain is the most common initial symptom. In contrast, pain is generally absent early in the course of radiation myelopathy and is never a prominent symptom. Local pain and root pain are particularly unusual. The onset of radiation myelopathy is insidious, and the progression is slow, over a period of months to years. The disease may become arrested before paraplegia supervenes. In contrast, the symptoms of intramedullary metastasis begin abruptly and progress steadily, over a period of days to weeks, to paraplegia. But exceptional patients with a slow progression of symptoms, over months or years, have been reported (06; 50; 22); so, a slow tempo favors the diagnosis of radiation myelopathy, but it does not exclude intramedullary metastasis.
The location of the primary tumor and past exposure to therapeutic radiation are oncologic features useful in separating intramedullary metastasis from radiation myelopathy. Sixty-four percent of patients with intramedullary metastasis have lung or breast cancer, and less than 1% have tumors of the head and neck (44). In contrast, more than 80% of patients with radiation myelopathy have tumors of the head and neck, and only 6% have carcinoma of the lung or breast (50). This is probably due to the low frequency with which head and neck tumors spread hematogenously and to the large doses of radiation used to treat them.
The diagnosis of radiation myelopathy should not be based on a vague incrimination of a past course of radiation therapy. The occurrence of radiation myelopathy is dose-related. The risk increases with a higher total and fractional dose of radiation, a shorter treatment time, and a greater length of spinal cord irradiated. A total dose of 5000 cGy given in 25 fractions over 5 weeks is safe for most patients. A delay of at least 4 months between exposure and the onset of spinal symptoms is characteristic. In addition, the full extent of the spinal cord lesion, determined by clinical means, must fall within the portal of radiation for the diagnosis to be tenable. Increased bone marrow signal on T1-weighted MR images is helpful in identifying the spinal levels irradiated. MRI may show abnormal signal in spinal cord segments just outside the radiation portal, most likely representing edema, but the major focus of the lesion and gadolinium enhancement lies within the portal (30; 29).
Both intramedullary metastasis and radiation myelopathy typically show increased signal on T2-weighted MR images, decreased signal on T1-weighted images, and a central area of diffuse, ring, or crescent-shaped enhancement, and both can cause secondary syringomyelia (08; 47; 35; 21). Two MRI features are of differential value. The spinal cord may be normal in size or enlarged in both diseases, but it undergoes atrophy in radiation myelopathy and appears small on imaging 8 to 10 months after the onset of symptoms (29; 47). Many patients with radiation myelopathy have normal MRI (01), but few with intramedullary spinal cord metastatic tumor do.
Intramedullary metastasis versus paraneoplastic myelopathy. Paraneoplastic necrotizing myelopathy was first described in 1964, by Mancall and Rosales. The neurologic features by which it differs from intramedullary spinal cord metastatic tumor are the presence of pain and the mode of progression of the myelopathy. Pain is absent or mild in necrotizing myelopathy, but it is a major symptom in intramedullary metastasis. The pathologic process of necrotizing myelopathy begins in the thoracic portion of the spinal cord and then ascends and descends in the cord (27). The descending progress is reflected clinically by paraplegia that changes from spastic and hyperreflexic to flaccid and areflexic or that is flaccid from the beginning and never becomes spastic. The ascending progress reveals itself as a sensory level rising segment by segment or as paraplegia becoming tetraplegia. Although this pattern of progression is characteristic of necrotizing myelopathy, the clinical deficit of intramedullary metastasis can progress in an identical manner, by 2 different mechanisms: the accumulation of metastases throughout the cord and progressive, so-called pencil-shaped necrosis of the spinal segments above and below the tumor (11; 50). Thus, although an ascending or descending progression of spinal signs is characteristic of necrotizing myelopathy, it is not pathognomonic, and its presence does not favor that diagnosis over intramedullary metastasis.
The presence of cerebral metastases is the only oncologic feature of value in separating intramedullary metastasis from necrotizing myelopathy. Cerebral metastases, often asymptomatic, are present in 61% of patients with intramedullary spinal cord metastasis but have been absent in all reported cases of paraneoplastic necrotizing myelopathy (50; 44). The myelographic and MRI features of intramedullary metastasis and necrotizing myelopathy are too similar to be of differential value (31; 46).
Flanagan and colleagues described paraneoplastic isolated myelopathy (07). Most patients, unlike those with intramedullary spinal cord metastatic tumor, have cerebrospinal fluid pleocytosis, and many have unique oligoclonal bands. Most patients also have neuronal autoantibodies in serum, mainly anti-Hu, anti-CRMP, or anti-amphiphysin. MRI shows symmetric, often enhancing and longitudinally extensive signal abnormality in long tracts or gray mattervery different from the MRI appearance of intramedullary spinal cord metastasis (40).
The same group of investigators from the Mayo Clinic described paraneoplastic myeloneuropathy (42). It resembles isolated paraneoplastic myelopathy, except that there are also clinical and electromyographic findings of polyneuropathy, in the form of polyradiculoneuropathy, sensorimotor polyneuropathy, or sensory ganglionopathy. MRI often shows enhancement of lumbar nerve roots. Like isolated paraneoplastic myelopathy, this illness differs from intramedullary spinal cord metastatic tumor in its MRI, cerebrospinal fluid, and serologic aspects.
Intramedullary spinal cord metastasis versus immune checkpoint inhibitor-associated myelitis. Immune checkpoints are cell-surface proteins that prevent T-lymphocytes from attacking the bodys normal tissue, but they also protect malignant tissue. Immune checkpoint inhibitors, a class of cancer chemotherapy, allow T-cells to attack cancer cells, but the drugs can create autoimmune diseases as side effects, of which 1% to 3% are neurologic. Myositis, peripheral neuropathy, and myasthenia gravis are the most common, but myelitis has been reported (28; 36), often associated with paraneoplastic neuronal autoantibodies in serum (23; 28). This myelitis resembles paraneoplastic isolated myelopathy and paraneoplastic myeloneuropathy in its clinical, MRI, cerebrospinal fluid, and serologic features, thus, distinguishing it from intramedullary spinal cord metastatic tumor should be relatively easy.
Intramedullary spinal cord versus leptomeningeal metastases. The characteristic picture of leptomeningeal metastasis is a combination of cerebral signs, cranial nerve palsies, and spinal radiculopathies; corticospinal tract signs are absent. Therefore, most cases of leptomeningeal metastasis are not mistaken for a focal, intramedullary lesion of the spinal cord, such as a metastatic tumor, with its upper border of segmental spinal signs, long-tract signs below, and absence of neurologic abnormalities above. However, 2 presentations of leptomeningeal metastasis can mimic intramedullary spinal cord metastasis. The cauda equina syndrome of leptomeningeal carcinomatosis is almost identical to the conus medullaris syndrome of a metastatic tumor, and leptomeningeal metastatic involvement of one or several neighboring spinal roots can cause the same localized root pain, segmental paresthesias, or monoparesis as a small metastatic tumor in the dorsal or ventral horn of the spinal cord. Such tumors may be too small for visualization by MRI. CSF examination will be positive for tumor cells in most patients with leptomeningeal metastasis. Of course, some patients have both intramedullary spinal and leptomeningeal metastatic tumor. The treatment of leptomeningeal metastasis consists of radiation directed to the site of major clinical involvement and, sometimes, intrathecal or intraventricular chemotherapy or systemic therapy. The treatment of intramedullary spinal cord metastasis is radiation therapy. If doubt remains as to which of these is the diagnosis, radiation therapy, with the portal determined by clinical localization of the spinal lesion, can be started while further diagnostic studies are carried out.
In patients not known to have cancer. Intramedullary spinal cord metastasis should be considered in the differential diagnosis of any acute or subacute myelopathy, especially in middle-aged or elderly patients. Rapid progression of an intramedullary metastatic tumor will suggest postinfectious, viral, or idiopathic transverse myelitis. Painful paraplegia appears so suddenly in some patients that the initial diagnosis may be myelomalacia or hematomyelia. A slowly growing metastatic tumor mimics spinal glioma or syringomyelia. A course denoting progressive, segment-by-segment destruction of the spinal cord will raise the question of acute or subacute necrotizing myelopathy. Although a sensitive test for intramedullary spinal lesions, MRI does not provide a specific diagnosis. Most patients with intramedullary spinal cord metastasis have primary or metastatic lung cancer and many have cerebral metastases; therefore, a search for underlying malignancy should include chest and head imaging.
Diagnostic workup
• MRI with and without contrast is the diagnostic procedure of choice for intramedullary spinal cord metastatic tumor. | |
• Intramedullary spinal cord metastatic tumor can take the form of a longitudinally extensive spinal cord lesion because of the necrotic spinal cord tissue adjacent to the tumor, but intravenous contrast will then reveal the hyperintense spherical mass in the center. | |
• Chest imaging will usually show primary or metastatic cancer in the lungs and metastatic tumor in the brain. |
Experience with imaging intramedullary spinal cord metastases has been recorded with oil-based myelography, myelography with water-soluble contrast and subsequent CT scanning, and MRI. Oil-based myelograms are normal in up to 50% of patients because the tumor is too small to enlarge the cord (05). CT-myelography is more sensitive, but false negatives remain (37). The most common myelographic abnormality is fusiform enlargement of the portion of the spinal cord that contains the tumor, sometimes with subarachnoid block (11). If the intramedullary tumor grows into the subarachnoid space or if leptomeningeal tumor invades the spinal cord, nodular filling defects or lobulated excrescences on the surface of the cord are seen (38). Sometimes, dilated tortuous veins like an arteriovenous malformation are present on the surface of the cord above the tumor (11).
MRI is the diagnostic procedure of choice. It shows the same gross alterations of size and shape as myelography, but it is more sensitive because it directly images the intramedullary spinal cord and detects tumors both large and small (37; 40) The tumor and the edematous or necrotic tissue around it appear hypointense to isointense on T1-weighted images and isointense to hyperintense on T2-weighted images.
With the infusion of gadolinium, the tumor enhances with a uniform or ring pattern, but the surrounding abnormal tissue does not. MRI also may show formation of a syringomyelic cavity adjacent to the tumor or hemorrhage in or around it. Other advantages of MRI over myelography include visualization of areas between myelographic blocks and easy imaging of the entire CNS, in order to diagnose asymptomatic metastases (37; 21).
The term longitudinally extensive spinal cord lesion refers to a continuous intramedullary lesion that is at least 3 contiguous vertebral segments long. Many types of myelitis can cause that MRI picture, including neuromyelitis optics, multiple sclerosis, acute disseminated encephalomyelitis, neurosarcoidosis, paraneoplastic isolated myelopathy, and myeloneuropathy. An intramedullary spinal cord metastatic tumor surrounded by segments of edematous or necrotic spinal cord tissue looks the same way, until contrast enhancement reveals the bright spherical mass in the center (40; 25).
Rykken and colleagues described 3 signs on contrast-enhanced MRI that can distinguish intramedullary metastatic from primary spinal cord tumors (39). The rim sign denotes the especially intense enhancement of a thin rim of the border of an enhancing metastatic tumor. The flame sign refers to a flame-shaped region of enhancement at the superior or inferior margin of an enhancing metastatic tumor. The central dot sign is a punctate focus of contrast enhancement in or near the center of an enhancing intramedullary mass. It is seen in some metastatic tumors and less often in primary ones.
PET can distinguish a metabolically active lesion, such as a tumor, from an inactive one, such as an area of necrotic tissue. The technique can at times be useful in distinguishing recurrent brain tumor from cerebral radiation necrosis. Likewise, it may help in separating intramedullary spinal cord metastatic tumor from radiation myelopathy, necrotizing myelopathy, and other spinal cord lesions (32).
Nonspecific abnormalities are usually found in the CSF of patients with intramedullary spinal cord metastatic tumor. In the largest series of patients, the median protein content was modestly increased (91 mg/dL) and ranged from normal to 1350 mg/dL (41). It is less than 200 mg/dL in most cases (06; 18; 05). Markedly elevated values reflect spinal subarachnoid block or extension of tumor into proximal nerve roots or the leptomeninges. In the large series of Schiff and O'Neill, the median leukocyte count was 3 cells/mm3 and ranged from 0 to 32 cells/mm3 (41). Most patients do not have a pleocytosis, and rarely is it greater than 20 cells/mm3 (18; 04). The cause of the pleocytosis is not known. Glucose levels are normal. Malignant cells are not found. In patients with both intramedullary spinal cord and leptomeningeal metastases, the CSF profile is in keeping with the latter disorder (41).
In patients not known to have cancer, part of the diagnosis of intramedullary metastasis consists in finding the primary tumor or metastases in other organs. Most patients have tumor in the lung, either primary or metastatic, and many patients have brain metastases as well (44). Imaging of the chest and head will usually show them. Biopsy of the spinal cord may be necessary if an underlying systemic malignancy is not found.
Management
• Radiation therapy is an effective treatment of intramedullary spinal cord metastatic tumor. | |
• It may be more effective when given as stereotactic radiosurgery than conventional fractionated external-beam radiotherapy. | |
• Some patients may benefit from surgical removal of an intramedullary spinal cord metastatic tumor. | |
• Targeted therapy may prove to be an effective treatment of some intramedullary spinal cord metastatic tumors. |
Radiation therapy. The literature on intramedullary spinal cord metastasis consists of several retrospective series of fewer than 10 patients, one series of 40 patients, also retrospective (41), and many literature reviews (11; 19; 44). No prospective controlled trials of treatment have been performed, and the condition is so uncommon that probably none ever will be. Although these are weak grounds for recommendations for treatment, certain things can be said with some confidence. Radiation therapy is an effective treatment for intramedullary metastatic tumors. Most patients will have stabilization of spinal cord function, and some patients will improve (19; 12). The effect of treatment is not short-lived; it usually lasts as long as the patient survives. The response to radiotherapy depends mainly on the degree and duration of the neurologic deficit when the patient enters treatment and much less on the radiosensitivity of the tumor (50; 41). Patients who cannot walk before treatment rarely walk afterward, but the ability to walk is usually preserved in those who can (41). Paraplegia that is present for days will not respond to treatment, but a minor deficit, such as segmental pain, paresthesias, or mild paraparesis, may resolve completely (50). A large tumor may disappear on MRI, but the patient may remain paraplegic. Most likely, the tumor has destroyed the segments of the cord that lodge it and caused necrosis of the adjacent ones as a complication. The tumor responds to radiation therapy, but the necrosis, of course, does not. In view of these points, the following formulation seems justified. Untreated, intramedullary spinal cord metastasis causes rapidly progressive paraplegia or tetraplegia. Radiation therapy can prevent that, but only if it is given early. Thus, intramedullary metastasis, like epidural spinal cord compression, qualifies as a neuro-oncologic emergency. Therefore, the diagnosis should be made and treatment started as soon as possible.
The spinal cord contains more than one intramedullary metastatic tumor in 20% of patients (40). Therefore, some authors have recommended that the entire spinal cord, not just the clinically involved portion, be treated with radiation, in order to prevent relapse elsewhere in the spinal cord and to avoid overlapping fields of consecutive courses of radiotherapy (50). However, only a few instances of such relapse have been recorded, and most patients will not survive long enough to develop delayed radiation myelopathy as a result of overlapping radiation portals (50). Thus, the risk of bone-marrow suppression from whole spinal cord irradiation probably outweighs the possible benefit. Focal radiation to the metastatic tumor and its margins should be given. The construction of the portal can be based on the MRI or myelogram or, if radiologic studies are normal, on the clinical localization of the tumor. Gadolinium enhancement on MRI localizes the tumor; abnormal signal intensity identifies not only the tumor, but also the edematous or necrotic segments of the spinal cord that surround it; hence, gadolinium enhancement should guide construction of the radiation portal. Patients should be followed closely for the appearance of symptoms of other metastatic tumors in the spinal cord, so that a second course of radiation therapy can be given while the neurologic deficit is still minor (50). Intrathecal or intraventricular chemotherapy can be given to patients who also have leptomeningeal metastatic disease.
Stereotactic radiosurgery was first applied to intramedullary spinal cord metastasis in 2004 and may be more effective than external-beam radiotherapy (14).
Surgery. Surgical removal of metastatic tumors from the spinal cord has been attempted. Some have concluded it is more effective than radiotherapy (26). The studies were small, retrospective, and uncontrolled; therefore, the conclusions are probably unreliable. Most patients with intramedullary metastases have widespread systemic and CNS metastatic disease and, therefore, will not be considered for surgery. At this time, surgery can be recommended for patients not known to have systemic cancer, because they need a tissue diagnosis, and for those whose neurologic deficit progresses during or after radiotherapy. It might be considered in a patient with no other metastases in the CNS, with well-controlled systemic disease, and with a radioresistant type of tumor. Once paraplegic, a patient should probably not be subjected to surgery because even extirpation of the tumor will not restore spinal cord function.
Systemic therapy. Some cancers are driven by oncogenes, ie, mutated genes that promote the uncontrolled growth of malignant tissue. Targeted therapy refers to inhibiting the products of those genes and has shown good results in non-small cell lung cancers. Pellerino and colleagues reported a patient with non-small cell lung cancer with the anaplastic lymphoma kinase oncogene who developed intramedullary spinal cord metastases (34). Treatment with the anaplastic lymphoma kinase inhibitors ceritinib and lorlatinib led to a complete response that lasted more than a year. Likewise, Horiuchi and colleagues reported a patient with lung adenocarcinoma whose intramedullary spinal cord metastasis responded to osimertinib, an inhibitor of epidermal growth factor receptor (16). If these or other targets, such as BRAF, are present in the primary tumor, the corresponding systemic targeted therapy should be considered because many have demonstrated CNS activity. Targeted therapy may prove to be an effective way to treat CNS metastatic disease, including intramedullary spinal cord metastases.
Special considerations
Pregnancy
No data are available in the literature on patients with intramedullary spinal cord metastases who are pregnant.
Anesthesia
There are no specific considerations concerning anesthesia in patients with intramedullary spinal cord metastases. Certain precautions must be observed in all patients with chronic spinal cord injuries, and they apply to patients with intramedullary metastatic tumors.
Media
References
- 01
- Alfonso ER, De Gregorio MA, Mateo P, et al. Radiation myelopathy in over-irradiated patients: MR imaging findings. Eur Radiol 1997;7(3):400-4. PMID 9087365
- 02
- Barron KD, Hirano A, Araki S, Terry RD. Experiences with metastatic neoplasms involving the spinal cord. Neurology 1959;9:91-106. PMID 13622902
- 03
- Belmusto L, Owens G, de la Pava S. Aspects of intramedullary spinal cord metastases. N Y State J Med 1966;66:2273-81.
- 04
- Costigan DA, Winkelman MD. Intramedullary spinal cord metastasis. A clinicopathologic study of 13 cases. J Neurosurg 1985;62:227-33. PMID 3968561
- 05
- Dunne JW, Harper CG, Pamphlett R. Intramedullary spinal cord metastases: a clinical and pathological study of nine cases. Q J Med 1986;61:1003-20. PMID 3659245
- 06
- Edelson RN, Deck M, Posner JB. Intramedullary spinal cord metastases. Clinical and radiographic findings in nine cases. Neurology 1972;22:1222-31. PMID 4346871
- 07
- Flanagan EP, McKeon A, Lennon VA, et al. Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues. Neurology 2011;76:2089-95. PMID 21670438
- 08
- Foster O, Crockard HA, Powell MP. Syrinx associated with intramedullary metastasis. J Neurol Neurosurg Psychiatry 1987;50:1067-70. PMID 3655816
- 09
- Fujimoto N, Hiraki A, Ueoka H, et al. Intramedullary spinal cord recurrence after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation for limited-disease small cell lung cancer. Lung Cancer 2000;30(2):145-8. PMID 11086208
- 10
- Gainor JF, Ou SH, Logan J, Borges LF, Shaw AT. The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer. J Thorac Oncol 2013;8(12):1570-3. PMID 24389440
- 11
- Grem JL, Burgess J, Trump D. Clinical features and natural history of intramedullary spinal cord metastasis. Cancer 1985;56:2305-14. PMID 4052974
- 12
- Hashii H, Mizumoto M, Kanemoto A, et al. Radiotherapy for patients with symptomatic intramedullary spinal cord metastasis. J Radiat Res 2011;52:641-5. PMID 21757849
- 13
- Hashizume Y, Hirano A. Intramedullary spinal cord metastasis. Pathologic findings in five autopsy cases. Acta Neuropathol 1983;61:214-8. PMID 6650133
- 14
- Hernandez-Duran S, Hanft S, Komotar RJ, Manzano GR. The role of stereotactic radiosurgery in the treatment of intramedullary spinal cord neoplasms: a systematic literature review. Neurosurg Rev 2016;39(2):175-83. PMID 26219855
- 15
- Hirose G, Shimazaki K, Takado M, Kosoegawa H, Ohya N, Mukawa A. Intramedullary spinal cord metastasis associated with pencil-shaped softening of the spinal cord. J Neurosurg 1980;52(5):718-21. PMID 7373403
- 16
- Horiuchi K, Asakura T, Sakaguchi S, Saito F. Successful osimertinib treatment in a patient who exhibited intramedullary spinal cord metastases of lung adenocarcinoma with an acquired EGFR T790M mutation. BMJ Case Rep 2019;12(6):e229310. PMID 31229973
- 17
- Jayakumar N, Ismail H, Athar S, Ashwood N. Perineural invasion in intramedullary spinal cord metastasis. Ann R Coll Surg Engl 2020;102(5):e94-6. PMID 32003581
- 18
- Jellinger K, Kothbauer P, Sunder-Plassmann E, Weiss R. Intramedullary spinal cord metastases. J Neurol 1979;220:31-41. PMID 84065
- 19
- Kalayci M, Cagavi F, Gul S, Yenidunya S, Acikgoz B. Intramedullary spinal cord metastases: diagnosis and treatmentan illustrated review. Acta Neurochir (Wien) 2004;146:1347-54. PMID 15526223
- 20
- Kawakami Y, Mair WG. Haematomyelia due to secondary renal carcinoma. Acta Neuropathol 1973;26:85-92. PMID 4747700
- 21
- Keung YK, Cobos E, Whitehead RP, Roberson GH. Secondary syringomyelia due to intramedullary spinal cord metastasis. Case report and review of the literature. Am J Clin Oncol 1997;20:577-9. PMID 9391544
- 22
- Koelman JH, De Visser M, Kuster JA, Dreissen JJ, Valk J, Koster PA. Intramedullary spinal cord metastasis following a slowly progressive course. J Neurol Neurosurg Psychiatry 1989;52(12):1451-2. PMID 2614459
- 23
- Kunchok A, Zekeridou A, Pittock S. CRMP5-IgG-associated paraneoplastic myelopathy with PD-L1 inhibitor therapy. JAMA Neurology 2020;77(2):255-6. PMID 31860013
- 24
- Lee SS, Kim MK, Sym SJ, et al. Intramedullary spinal cord metastases: a single-institution experience. J Neurooncol 2007;84:85-9. PMID 17310265
- 25
- Madhavan AA, Diehn FE, Rykken JB, et al. The central dot sign: a specific post-gadolinium enhancement feature of intramedullary spinal cord metastases. Clin Neuroradiol 2021;31(2):383-90. PMID 32382876
- 26
- Majmundar N, Shao B, Assina R. Lung adenocarcinoma presenting as intramedullary spinal cord metastasis: case report and review of literature. J Clin Neurosci 2018;52:124-31. PMID 29631755
- 27
- Mancall EL, Rosales RK. Necrotizing myelopathy associated with visceral carcinoma. Brain 1964;87:639-56. PMID 14236008
- 28
- Marini A, Bernardini A, Gigli G, et al. Neurologic adverse events of immune checkpoint inhibitors. Neurology 2021;96(16):754-66. PMID 33653902
- 29
- Melki PS, Halimi P, Wibault P, Masnou P, Doyon D. MRI in chronic progressive radiation myelopathy. J Comput Assist Tomogr 1994;18:1-6. PMID 8282856
- 30
- Michikawa M, Wada Y, Sano M, et al. Radiation myelopathy: significance of gadolinium-DTPA enhancement in the diagnosis. Neuroradiology 1991;33(3):286-9. PMID 1881553
- 31
- Mirich DR, Kucharczyk W, Keller MA, Deck J. Subacute necrotizing myelopathy: MR imaging in four pathologically proved cases. AJNR Am J Neuroradiol 1991;12(6):1077-83. PMID 1763730
- 32
- Mostardi PM, Diehn FE, Rykken JB, et al. Intramedullary spinal cord metastases: visibility on PET and correlation with MRI features. AJNR Am J Neuroradiol 2014;35(1):196-201. PMID 23886743
- 33
- Okamoto H, Shinkai T, Matsuno Y, Saijo N. Intradural parenchymal involvement in the spinal subarachnoid space with primary lung cancer. Cancer 1993;72:2583-8. PMID 8402479
- 34
- Pellerino A, Buffoni L, Ruda R, Soffietti R. Complete response of spinal metastases from non-small cell lung cancer with ALK inhibitors. Neurology 2019;93(5):217-19. PMID 31248938
- 35
- Phuphanich S, Jacobs M, Murtagh FR, Gonsalro A. MRI of spinal cord radiation necrosis simulating recurrent cervical cord astrocytoma and syringomyelia. Surg Neurol 1996;45:362-5. PMID 8607087
- 36
- Picca A, Berzero G, Bihan K, et al. Longitudinally extensive myelitis associated with immune checkpoint inhibitors. Neurol Neuorimmunol Neuroinflamm 2021;8(3):e967. PMID 33637598
- 37
- Post MJ, Quencer RM, Green BA, et al. Intramedullary spinal cord metastases, mainly of nonneurogenic origin. AJR Am J Roentgenol 1987;148(5):1015-22. PMID 3554916
- 38
- Prentice WB, Kiefer SA, Gold LH, Bjornson RG. Myelographic characteristics of metastasis of the spinal cord and cauda equina. Am J Roentgenol Radium Ther Nucl Med 1973;118(3):682-9. PMID 4579216
- 39
- Rykken JB, Diehn FE, Hunt CH, et al. Rim and flame signs: postgadolinium MRI findings specific for non-CNS intramedullary spinal cord metastases. Am J Neuroradiol 2013a;34:908-15. PMID 23079405
- 40
- Rykken JB, Diehn FE, Hunt CH, et al. Intramedullary spinal cord metastases: MRI and relevant clinical features from a 13-year institutional case series. AJNR Am J Neuroradiol 2013b;34(10):2043-9. PMID 23620071
- 41
- Schiff D, O'Neill BP. Intramedullary spinal cord metastases: clinical features and treatment outcome. Neurology 1996;47:906-12. PMID 8857717
- 42
- Shah S, Vazquez do Campo R, Kumar N, et al. Paraneoplastic myeloneuropathies: clinical, oncologic, and serologic accompaniments. Neurology 2021;96(4):e632-9. PMID 33208548
- 43
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70(1):7-30. PMID 31912902
- 44
- Sung WS, Sung MJ, Chan JH, et al. Intramedullary spinal cord metastases: a 20-year institutional experience with a comprehensive literature review. World Neurosurg 2013;79:576-84. PMID 22484768
- 45
- Tognetti F, Lanzino G, Calbucci F. Metastases of the spinal cord from remote neoplasms. Study of five cases. Surg Neurol 1988;30:220-7. PMID 3413668
- 46
- Urai Y, Matsumoto K, Shimamura M, et al. Paraneoplastic necrotizing myelopathy in a patient with advanced esophageal cancer: An autopsied case report. J Neurol Sci 2009;280(1-2):113-7. PMID 19272613
- 47
- Wang PY, Shen WC, Jan JS. Serial MRI changes in radiation myelopathy. Neuroradiology 1995;37:374-7. PMID 7477837
- 48
- Weissman DE, Grossman SA. Simultaneous leptomeningeal and intramedullary spinal metastases in small cell lung carcinoma. Med Pediatr Oncol 1986;14:54-6. PMID 3005816
- 49
- Willis RA. The spread of tumours in the human body. London: J & A Churchill, 1934.
- 50
- Winkelman MD, Adelstein DJ, Karlins NL. Intramedullary spinal cord metastasis. Diagnostic and therapeutic considerations. Arch Neurol 1987;44:526-31. PMID 3579664
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Marc D Winkelman MD
Dr. Winkelman of Case Western Reserve University has no relevant financial relationships to disclose.
See Profile
Editor
-
Deric M Park MD FACP
Dr. Park of the University of Chicago has no relevant financial relationships to disclose.
See Profile
Former Authors
- Rimas V Lukas MD
Patient Profile
- Age range of presentation
-
- 13 to 65+ years
- Sex preponderance
-
- male>female, >1:1
- Heredity
-
- none
- Population groups selectively affected
-
- none selectively affected
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-9
-
- Secondary malignant neoplasm of brain and spinal cord: 198.3
- ICD-10
-
- Secondary malignant neoplasm of brain and cerebral meninges: C79.3
- ICD-O
-
- Neoplasm, malignant: M8000/3
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Neuro-Oncology
Tumors of the skull base
Dec. 05, 2024
-
Neuro-Oncology
Ganglioglioma
Oct. 15, 2024
-
Neuro-Oncology
Paraneoplastic syndromes
Oct. 15, 2024
-
Neuro-Oncology
Overview of neuropathology updates for infiltrating gliomas
Oct. 11, 2024
-
Neuro-Oncology
NTRK-fused tumors of the central nervous system
Oct. 07, 2024
-
Neuro-Oncology
Anti-LGI1 encephalitis
Oct. 03, 2024
-
Neuro-Oncology
Brain metastases
Oct. 03, 2024